Management of venous thromboembolism in patients with cancer: role of dalteparin

Review

(2185) Views  (384) Full article downloads

Author: Lori-Ann Linkins

Published Date May 2008 Volume 2008:4(2) Pages 279 - 287

DOI: http://dx.doi.org/10.2147/VHRM.S2132

Lori-Ann Linkins

Department of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, Canada

Abstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.

Keywords: dalteparin, cancer, venous thromboembolism